Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pyxis Oncology (PYXS) Liabilities and Shareholders Equity (2024 - 2025)

Pyxis Oncology (PYXS) has disclosed Liabilities and Shareholders Equity for 2 consecutive years, with $91.5 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity fell 41.77% to $91.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $456.2 million through Dec 2025, down 41.59% year-over-year, with the annual reading at $91.5 million for FY2025, 41.77% down from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $91.5 million at Pyxis Oncology, down from $105.6 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $220.2 million in Q1 2024, with the low at $91.5 million in Q4 2025.